Lisuride: Difference between revisions

	WikiDoc Resources for Lisuride
Articles
Most recent articles on Lisuride Most cited articles on Lisuride Review articles on Lisuride Articles on Lisuride in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Lisuride Images of Lisuride Photos of Lisuride Podcasts & MP3s on Lisuride Videos on Lisuride
Evidence Based Medicine
Cochrane Collaboration on Lisuride Bandolier on Lisuride TRIP on Lisuride
Clinical Trials
Ongoing Trials on Lisuride at Clinical Trials.gov Trial results on Lisuride Clinical Trials on Lisuride at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Lisuride NICE Guidance on Lisuride NHS PRODIGY Guidance FDA on Lisuride CDC on Lisuride
Books
Books on Lisuride
News
Lisuride in the news Be alerted to news on Lisuride News trends on Lisuride
Commentary
Blogs on Lisuride
Definitions
Definitions of Lisuride
Patient Resources / Community
Patient resources on Lisuride Discussion groups on Lisuride Patient Handouts on Lisuride Directions to Hospitals Treating Lisuride Risk calculators and risk factors for Lisuride
Healthcare Provider Resources
Symptoms of Lisuride Causes & Risk Factors for Lisuride Diagnostic studies for Lisuride Treatment of Lisuride
Continuing Medical Education (CME)
CME Programs on Lisuride
International
Lisuride en Espanol Lisuride en Francais
Business
Lisuride in the Marketplace Patents on Lisuride
Experimental / Informatics
List of terms related to Lisuride

Lisuride
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral, subcutaneous, transdermal
ATC code	G02CB02 (WHO) N02CA07 (WHO);
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	10-20% for lisuride hydrogen maleate
Protein binding	about 15%
Metabolism	Hepatic
Elimination half-life	2 hours
Excretion	renal and biliary in equal amounts
Identifiers
	IUPAC name 1,1-Diethyl-3-(7-methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinolin-9-yl)-urea;
CAS Number	18016-80-3 ;
PubChem CID	28864;
IUPHAR/BPS	227;
DrugBank	DB00589 ;
ChemSpider	26847 ;
UNII	E0QN3D755O;
KEGG	D08132 ;
ChEBI	CHEBI:51164 ;
ChEMBL	ChEMBL157138 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C20H26N4O
Molar mass	338.447 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=C(N(CC)CC)N[C@H]3/C=C2/c4cccc1c4c(cn1)C[C@H]2N(C3)C;
	InChI InChI=1S/C20H26N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,10-11,14,18,21H,4-5,9,12H2,1-3H3,(H,22,25)/t14-,18+/m0/s1 ; Key:BKRGVLQUQGGVSM-KBXCAEBGSA-N ;
(verify)

← Older edit Newer edit →

VisualWikitext

Revision as of 13:02, 10 April 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Lisuride (brand name in Germany Dopergin) is an anti-Parkinson's drug of the iso-ergoline class, chemically related to the dopaminergic ergoline Parkinson's drugs. Lisuride is described as free base (see table on the right) and as hydrogenmaleate salt.

Lisuride is used to lower prolactin and, in low doses, to prevent migraine attacks. The use of lisuride as initial anti-Parkinsonian treatment has been advocated, delaying the need for levodopa until lisuride becomes insufficient for controlling the Parkinsonian disability. Preliminary trials suggest that the dermal application of lisuride may be useful in the treatment of Parkinson's disease. Lisuride is not currently available in the US.

Lisuride (Dopergin, Proclacam, Revanil) is an antiparkinson agent of the iso-ergoline class, chemically related to the dopaminergic ergoline Parkinson's drugs. Lisuride is described as free base (see table on the right) and as hydrogen maleate salt.

Lisuride is used to lower prolactin and, in low doses, to prevent migraine attacks. The use of lisuride as initial anti-Parkinsonian treatment has been advocated, delaying the need for levodopa until lisuride becomes insufficient for controlling the Parkinsonian disability. Preliminary trials suggest that the dermal application of lisuride may be useful in the treatment of Parkinson's disease. As lisuride is very poorly absorbed when take orally and has a short half-life, continuous transdermal administration offers significant advantages and could make the compound a far more consistent therapeutic. Lisuride is not currently available in the US, as the drug was not a commercial success in comparison with other dopamine receptor agonist anti-parkinsonian compounds. It is still used clinically in a number of countries in the EU and is still commercially available in the UK and China.

A Study has failed to find any association between lisuride and fibrotic cardiac valvulopathy.^[1]

Mode of action

Lisuride is a dopamine and serotonin receptor partial agonist. It has a high affinity for the dopamine D2, D3 and D4 receptors, as well as serotonin 5-HT1A^[2] and 5-HT2A/C receptors.^[3] While lisuride has a similar receptor binding profile to the more well-known and chemically similar ergoloid N,N-diethyl-lysergamide (LSD) and inhibits dorsal raphe serotonergic neurons in a similar fashion to LSD,^[4] it lacks the psychedelic effects of its sister compound. It has been suggested that this may be because lisuride acts as an agonist at 5-HT1A and 5-HT2A subtypes but behaves as an antagonist at 5-HT2C, inhibiting the psychedelic effect.^[5] Newer findings suggest that the lack of psychedelic action arises from the phenomenon of biased agonism. Stimulation of the 5-HT2A protomer within the 5-HT2A-mGlu2 receptor complex evokes psychedelic effects, while these effects do not occur during sole stimulation of monomeric 5-HT2A receptors. Accordingly, different G-proteins are involved.^[6]^[7] Lisurid behaves as an agonist at the 5-HT2AR monomer. Since it competitively antagonises the effects of LSD, it may be regarded as a protomer antagonist of the 5-HT2A-mGluR heteromer.^[8] GPCR oligomers are discrete entities and usually possess properties distinct from their parent monomeric receptors.

Commercial names

Name	Country of Use
Arolac	France
Cuvalit	Germany
Dipergon	Greece
Dopergin(e)	Germany, Spain, France, China
Dopergine	Belgium
Lysenyl Forte	Czech Republic, Slovakia
Prolacam	Australia
Revanil	UK

History

Synthesis of lisuride was first described in 1960.

Indications

Parkinson's Disease

References

↑ "Lisuride, a dopamine receptor ag... [Clin Neuropharmacol. 2006 Mar-Apr] - PubMed - NCBI". Retrieved 10 February 2014.
↑ Marona-Lewicka D, Kurrasch-Orbaugh DM, Selken JR, Cumbay MG, Lisnicchia JG, Nichols DE (October 2002). "Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats". Psychopharmacology (Berl.). 164 (1): 93–107. doi:10.1007/s00213-002-1141-z. PMID 12373423.
↑ Egan CT, Herrick-Davis K, Miller K, Glennon RA, Teitler M (April 1998). "Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors". Psychopharmacology (Berl.). 136 (4): 409–14. doi:10.1007/s002130050585. PMID 9600588.
↑ Rogawski MA, Aghajanian GK (1979). "Response of central monoaminergic neurons to lisuride: comparison with LSD". Life Sci. 24 (14): 1289–1297. PMID 470543. line feed character in |title= at position 45 (help)
↑ Template:Cite doi
↑ Moreno JL, Holloway T, Albizu L, Sealfon SC, González-Maeso J (2011). "Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists". Neurosci. Lett. 493 (3): 76–9. doi:10.1016/j.neulet.2011.01.046. PMC 3064746. PMID 21276828.
↑ González-Maeso J, Ang RL, Yuen T; et al. (2008). "Identification of a serotonin/glutamate receptor complex implicated in psychosis". Nature. 452 (7183): 93–7. doi:10.1038/nature06612. PMC 2743172. PMID 18297054.
↑ González-Maeso J et al. (2007): "Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior", Neuron, Bd. 53, S. 439. PMID 17270739

[www.ncbi.nlm.nih.gov-1] "Lisuride, a dopamine receptor ag... [Clin Neuropharmacol. 2006 Mar-Apr] - PubMed - NCBI". Retrieved 10 February 2014.

[pmid12373423-2] Marona-Lewicka D, Kurrasch-Orbaugh DM, Selken JR, Cumbay MG, Lisnicchia JG, Nichols DE (October 2002). "Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats". Psychopharmacology (Berl.). 164 (1): 93–107. doi:10.1007/s00213-002-1141-z. PMID 12373423.

[pmid9600588-3] Egan CT, Herrick-Davis K, Miller K, Glennon RA, Teitler M (April 1998). "Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors". Psychopharmacology (Berl.). 136 (4): 409–14. doi:10.1007/s002130050585. PMID 9600588.

[pmid470543-4] Rogawski MA, Aghajanian GK (1979). "Response of central monoaminergic neurons to lisuride: comparison with LSD". Life Sci. 24 (14): 1289–1297. PMID 470543. line feed character in |title= at position 45 (help)

[5] Template:Cite doi

[6] Moreno JL, Holloway T, Albizu L, Sealfon SC, González-Maeso J (2011). "Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists". Neurosci. Lett. 493 (3): 76–9. doi:10.1016/j.neulet.2011.01.046. PMC 3064746. PMID 21276828.

[7] González-Maeso J, Ang RL, Yuen T; et al. (2008). "Identification of a serotonin/glutamate receptor complex implicated in psychosis". Nature. 452 (7183): 93–7. doi:10.1038/nature06612. PMC 2743172. PMID 18297054.

[8] González-Maeso J et al. (2007): "Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior", Neuron, Bd. 53, S. 439. PMID 17270739

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

@@ Line 1: / Line 1: @@
-__NOTOC__
-{{Lisuride}}
-{{CMG}}; {{AE}} {{PB}}
-'''''For patient information about Lisuride, click [[Lisuride (patient information)|here]]'''''
 {{Drugbox
 | Watchedfields = changed
 | verifiedrevid = 462092223
 | IUPAC_name = 1,1-Diethyl-3-(7-methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinolin-9-yl)-urea
-| image = Lisuride.svg
+| image =Lisuride.png
 <!--Clinical data-->
@@ Line 57: / Line 51: @@
 | StdInChIKey = BKRGVLQUQGGVSM-KBXCAEBGSA-N
 }}
+__Notoc__
+{{SI}}
+{{CMG}}
 ==Overview==
@@ Line 129: / Line 125: @@
 [[Category:Ureas]]
-[[de:Lisurid]]
@@ Line 136: / Line 132: @@
 {{Reflist|2}}
+[[Category:Drug]]
 [[Category:Cardiovascular Drugs]]
 [[Category:Drugs]]

Lisuride: Difference between revisions

Revision as of 13:02, 10 April 2015

Overview

Mode of action

Commercial names

History

Indications

See also

References

Navigation menu

Clinical data

AHFS/Drugs.com	International Drug Names
Routes of administration	Oral, subcutaneous, transdermal
ATC code	G02CB02 (WHO) N02CA07 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	10-20% for lisuride hydrogen maleate
Protein binding	about 15%
Metabolism	Hepatic
Elimination half-life	2 hours
Excretion	renal and biliary in equal amounts
Identifiers
IUPAC name 1,1-Diethyl-3-(7-methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinolin-9-yl)-urea
CAS Number	18016-80-3^Y
PubChem CID	28864
IUPHAR/BPS	227
DrugBank	DB00589^Y
ChemSpider	26847^Y
UNII	E0QN3D755O
KEGG	D08132^Y
ChEBI	CHEBI:51164^Y
ChEMBL	ChEMBL157138^Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₀H₂₆N₄O
Molar mass	338.447 g/mol
3D model (JSmol)	Interactive image
SMILES O=C(N(CC)CC)N[C@H]3/C=C2/c4cccc1c4c(cn1)C[C@H]2N(C3)C
InChI InChI=1S/C20H26N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,10-11,14,18,21H,4-5,9,12H2,1-3H3,(H,22,25)/t14-,18+/m0/s1^Y Key:BKRGVLQUQGGVSM-KBXCAEBGSA-N^Y
(verify)

Lisuride: Difference between revisions

Revision as of 13:02, 10 April 2015

Overview

Mode of action

Commercial names

History

Indications

See also

References

Navigation menu

Search